EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections

Jake Crocker, Ismael Yunusa, P Brandon Bookstaver, Caroline Derrick, Julie Ann Justo, Bruce M Jones, Bryan P White, Joseph Sassine iD, Madeline Belk, Morgan Pizzuti

American Journal of Health-System Pharmacy · 07.04.2026 · 83 (8) · 389-397

DOI: 10.1093/ajhp/zxaf301 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 31.10.2025. Verfasst von Jake Crocker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Prisma Health Upstate, Greenville, SC, USA. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Emerging data suggest dalbavancin may be used in complicated infections, including bacteremia, prosthetic joint infections, osteomyelitis, and endovascular infections. This study aimed to evaluate the real-world safety and effectiveness of dalbavancin for the treatment of invasive gram-positive infections (GPIs).

Methods

This multicenter, retrospective cohort study included adult patients who received dalbavancin for treatment of confirmed or presumed invasive GPIs. Patients were excluded if they received dalbavancin for chronic suppression. The intention-to-treat (ITT) population comprised patients who received at least 1 dalbavancin dose. The per-protocol (PP) population received at least 2 doses. The primary outcome was clinical failure in the PP group at 90 days post treatment. Secondary outcomes were the proportion of logistical failures, clinical failures, and treatment-emergent adverse events in the ITT group at 90 days post treatment.

Results

Among the 194 patients included in the PP population, 29.4% (57/194) experienced clinical failure at 90 days post treatment. Active intravenous drug use and lack of reliable transportation were factors significantly associated with higher odds of clinical failure in a multivariable regression model.

Conclusion

Dalbavancin is a safe and effective treatment option for invasive GPIs; however, risk factors are associated with higher odds of clinical failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeicoplaninAnti-Bacterial AgentsGram-Positive Bacterial InfectionsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedTreatment OutcomeAdultCohort StudiesAged, 80 and over

Stichwörter der Autor:innen

Staphylococcus aureusIVDUdalbavancinlipoglycopeptidetransitions of caretreatment failure

Substanzen

dalbavancinTeicoplaninAnti-Bacterial Agents

Autor:innen und Institutionen

  • Prisma Health Upstate, Greenville, SC, USA.
  • University of South Carolina College of Pharmacy, Columbia, SC, USA.
  • Prisma Health Richland, Columbia, SC, USA.
  • Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
  • St. Joseph's/Candler Health System, Savannah, GA, USA.
  • University of Oklahoma Medical Center at OU Health, Oklahoma City, OK, USA.

ORCID-Profile: Joseph Sassine

Zitieren

APA

Crocker, J., Yunusa, I., Bookstaver, P. B., Derrick, C., Justo, J. A., Jones, B. M., White, B. P., Sassine, J., Belk, M., & Pizzuti, M. (2026). Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections. American Journal of Health-System Pharmacy, 83(8), 389-397. https://doi.org/10.1093/ajhp/zxaf301

Vancouver

Crocker J, Yunusa I, Bookstaver PB, Derrick C, Justo JA, Jones BM, et al. Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections. American Journal of Health-System Pharmacy. 2026;83(8):389-397. doi:10.1093/ajhp/zxaf301

BibTeX
@article{Crocker2026,
  author = {Crocker, Jake and Yunusa, Ismael and Bookstaver, P Brandon and Derrick, Caroline and Justo, Julie Ann and Jones, Bruce M and White, Bryan P and Sassine, Joseph and Belk, Madeline and Pizzuti, Morgan},
  title = {Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections},
  journal = {American Journal of Health-System Pharmacy},
  year = {2026},
  volume = {83},
  number = {8},
  pages = {389--397},
  doi = {10.1093/ajhp/zxaf301}
}
Kostenlos starten →